See more : TENDA Co.,LTD. (4198.T) Income Statement Analysis – Financial Results
Complete financial analysis of InfuSystem Holdings, Inc. (INFU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InfuSystem Holdings, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Satu Holdings Limited (8392.HK) Income Statement Analysis – Financial Results
- Caravel Minerals Limited (CVV.AX) Income Statement Analysis – Financial Results
- Barrick Gold Corporation (ABR.DE) Income Statement Analysis – Financial Results
- Wiziboat SA (MLWIZ.PA) Income Statement Analysis – Financial Results
- Landis+Gyr Group AG (LGYRF) Income Statement Analysis – Financial Results
InfuSystem Holdings, Inc. (INFU)
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 125.79M | 109.91M | 102.38M | 97.39M | 81.12M | 67.14M | 71.08M | 70.50M | 72.13M | 66.49M | 62.28M | 58.83M | 54.64M | 47.23M | 38.96M | 35.42M | 6.58M | 0.00 | 0.00 |
Cost of Revenue | 62.68M | 47.34M | 42.19M | 38.63M | 34.23M | 28.12M | 27.72M | 25.76M | 20.94M | 19.13M | 18.60M | 15.92M | 19.28M | 13.68M | 10.33M | 9.19M | 1.62M | 0.00 | 0.00 |
Gross Profit | 63.11M | 62.57M | 60.20M | 58.76M | 46.88M | 39.02M | 43.36M | 44.74M | 51.18M | 47.35M | 43.68M | 42.91M | 35.36M | 33.55M | 28.64M | 26.22M | 4.96M | 0.00 | 0.00 |
Gross Profit Ratio | 50.17% | 56.93% | 58.80% | 60.33% | 57.80% | 58.12% | 61.01% | 63.46% | 70.97% | 71.22% | 70.13% | 72.94% | 64.71% | 71.03% | 73.50% | 74.05% | 75.39% | 0.00% | 0.00% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 45.38M | 46.08M | 42.26M | 35.20M | 29.02M | 24.85M | 25.20M | 24.63M | 23.78M | 19.99M | 18.97M | 23.06M | 17.99M | 20.62M | 12.22M | 11.77M | 4.89M | 919.22B | 0.00 |
Selling & Marketing | 12.65M | 12.26M | 10.78M | 9.66M | 9.93M | 9.11M | 9.78M | 9.66M | 10.42M | 9.75M | 9.66M | 9.86M | 9.37M | 7.09M | 5.26M | 4.66M | 649.00K | -919.20B | 0.00 |
SG&A | 58.03M | 58.34M | 53.04M | 44.86M | 38.96M | 33.95M | 34.98M | 34.29M | 34.20M | 29.73M | 28.63M | 32.93M | 27.36M | 27.71M | 17.48M | 16.42M | 6.12M | 20.82M | 24.48K |
Other Expenses | 990.00K | 2.58M | 4.34M | 5.08M | 4.40M | -37.00K | -113.00K | 6.00K | 13.00K | 13.00K | 301.00K | -141.00K | 6.76M | 6.77M | 5.83M | 5.01M | 6.46M | 20.82M | 0.00 |
Operating Expenses | 59.02M | 60.92M | 57.38M | 49.93M | 43.36M | 38.60M | 46.18M | 43.77M | 42.32M | 38.02M | 37.78M | 40.91M | 34.12M | 34.48M | 23.31M | 21.44M | 6.46M | 20.82M | 24.48K |
Cost & Expenses | 121.70M | 108.26M | 99.56M | 88.56M | 77.59M | 66.72M | 73.90M | 69.52M | 63.26M | 57.16M | 56.38M | 56.83M | 53.40M | 48.17M | 33.64M | 30.63M | 8.08M | 20.82M | 24.48K |
Interest Income | 0.00 | 1.40M | 1.38M | 1.26M | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 36.00K | 3.88M | 3.20M | 0.00 |
Interest Expense | 2.17M | 1.40M | 1.38M | 1.26M | 1.90M | 1.42M | 1.33M | 1.34M | 1.71M | 3.13M | 3.50M | 3.34M | 2.19M | 3.35M | 3.50M | 3.77M | 774.00K | 1.30K | 300.00 |
Depreciation & Amortization | 12.51M | 13.36M | 14.63M | 14.03M | 12.34M | 11.31M | 12.52M | 10.74M | 8.24M | 6.14M | 8.03M | 8.40M | 9.05M | 8.60M | 6.44M | 6.40M | 862.00K | 6.66M | 0.00 |
EBITDA | 16.50M | 15.09M | 17.15M | 22.82M | 15.77M | 11.69M | 8.60M | 11.72M | 13.94M | 15.49M | 14.23M | 9.45M | -57.34M | 7.75M | 11.69M | 20.40M | -635.00K | -6.82M | -24.48K |
EBITDA Ratio | 13.11% | 13.55% | 16.86% | 23.44% | 19.44% | 17.41% | 13.49% | 16.63% | 23.74% | 23.29% | 22.85% | 17.44% | 18.82% | 16.21% | 30.22% | 31.70% | 40.40% | 0.00% | 0.00% |
Operating Income | 4.09M | 1.65M | 2.82M | 8.83M | 3.53M | 415.00K | -3.81M | 974.00K | 8.86M | 9.33M | 5.90M | 2.00M | -66.36M | -938.00K | 5.33M | 4.79M | -1.50M | -20.82M | -24.48K |
Operating Income Ratio | 3.25% | 1.50% | 2.75% | 9.06% | 4.35% | 0.62% | -5.36% | 1.38% | 12.29% | 14.03% | 9.47% | 3.40% | -121.45% | -1.99% | 13.67% | 13.51% | -22.74% | 0.00% | 0.00% |
Total Other Income/Expenses | -2.24M | -1.52M | -1.56M | -1.28M | -2.00M | -1.46M | -1.45M | -1.34M | -3.29M | -3.12M | -3.20M | -4.15M | -2.22M | -2.29M | -3.58M | 6.08M | -189.00K | -6,821.45B | 0.00 |
Income Before Tax | 1.85M | 130.00K | 1.26M | 7.54M | 1.52M | -1.04M | -5.26M | -364.00K | 5.57M | 6.21M | 2.70M | -2.15M | -68.58M | -3.22M | 1.75M | 10.87M | -1.69M | -6.82M | 0.00 |
Income Before Tax Ratio | 1.47% | 0.12% | 1.23% | 7.75% | 1.88% | -1.55% | -7.40% | -0.52% | 7.73% | 9.34% | 4.34% | -3.66% | -125.51% | -6.82% | 4.49% | 30.68% | -25.62% | 0.00% | 0.00% |
Income Tax Expense | 979.00K | 112.00K | -163.00K | -9.79M | 163.00K | 53.00K | 15.45M | -142.00K | 1.83M | 2.85M | 1.03M | -663.00K | -23.13M | -1.37M | 977.00K | 907.00K | 1.11M | 1.04M | 24.78K |
Net Income | 872.00K | 18.00K | 1.42M | 17.33M | 1.36M | -1.10M | -20.71M | -222.00K | 3.74M | 3.36M | 1.67M | -1.49M | -45.44M | -1.85M | 774.00K | 9.96M | -2.80M | -7.86M | -24.78K |
Net Income Ratio | 0.69% | 0.02% | 1.39% | 17.80% | 1.68% | -1.63% | -29.13% | -0.31% | 5.19% | 5.05% | 2.68% | -2.53% | -83.17% | -3.92% | 1.99% | 28.12% | -42.48% | 0.00% | 0.00% |
EPS | 0.04 | 0.00 | 0.07 | 0.86 | 0.07 | -0.05 | -0.91 | -0.01 | 0.17 | 0.15 | 0.08 | -0.07 | -2.16 | -0.09 | 0.04 | 0.56 | -0.15 | -0.58 | -0.01 |
EPS Diluted | 0.04 | 0.00 | 0.06 | 0.80 | 0.07 | -0.05 | -0.91 | -0.01 | 0.16 | 0.15 | 0.08 | -0.07 | -2.16 | -0.09 | 0.04 | 0.53 | -0.15 | -0.58 | -0.01 |
Weighted Avg Shares Out | 21.02M | 20.65M | 20.52M | 20.11M | 19.73M | 21.42M | 22.74M | 22.20M | 22.41M | 22.15M | 21.87M | 21.27M | 21.07M | 19.72M | 18.61M | 17.94M | 18.30M | 13.66M | 3.25M |
Weighted Avg Shares Out (Dil) | 21.65M | 21.55M | 22.05M | 21.72M | 20.84M | 21.42M | 22.74M | 22.62M | 22.84M | 22.55M | 22.07M | 21.43M | 21.07M | 19.72M | 18.93M | 18.67M | 18.30M | 13.66M | 3.25M |
InfuSystem to Announce Full Year 2021 Guidance on Tuesday, December 15, 2020
InfuSystem to Present at Craig-Hallum Capital Group and Sidoti & Company Investment Conferences
InfuSystem to Report Third Quarter 2020 Financial Results on Thursday, November 12, 2020
Infusion Pump Market 2020 Industry Analysis, Forthcoming Growth, Industry Prospects and Forecast to 2030
Materials for Infusion Disposables Market Size 2020–Global Industry Analysis, Trends, Market Demand, Growth, Opportunities and Forecast 2026
Email Marketing Software Market 2020 Global Industry Size, Demand, Share, Growth Analysis, CAGR Status, Revenue and 2026 Forecast
InfuSystem Holdings Inc. (INFU) CEO Rich Dilorio on Q2 2020 Results - Earnings Call Transcript
State Street Corp Invests $116,000 in InfuSystem Holdings Inc (NYSEAMERICAN:INFU)
Intravenous Stopcock Market to Surpass US$ 570.4 Million globally by end of 2027, Says CMI
Source: https://incomestatements.info
Category: Stock Reports